Table 2.
Initial Equivalence of Study Arms on Sociodemographic, Prognostic, Treatment, and Performance Status Variables
| Total (N = 227)
|
Assessment (n = 113)
|
Intervention (n = 114)
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Mean | % | SD | Mean | % | SD | Mean | % | SD |
| Sociodemographic | |||||||||
| Age, years | 50.82 | 10.76 | 51.07 | 10.89 | 50.56 | 10.68 | |||
| Race, % white | 90 | 90 | 90 | ||||||
| Education, years | 14.75 | 2.74 | 14.34 | 2.57 | 15.16 | 2.85 | |||
| Family income, thousand $/year | 67.98 | 71.41 | 66.30 | 84.68 | 69.64 | 55.59 | |||
| Marital status, % married | 67 | 67 | 67 | ||||||
| Significant other, % yes | 74 | 72 | 75 | ||||||
| Prognostic | |||||||||
| Stage, II v III, %II | 90 | 92 | 89 | ||||||
| Nodes, No. positive | 3.05 | 5.45 | 3.06 | 5.27 | 3.04 | 5.64 | |||
| Tumor size, cm | 3.02 | 1.77 | 2.91 | 1.75 | 3.12 | 1.78 | |||
| ER/PR, % positive | 68 | 68 | 68 | ||||||
| Menopausal status, % premenopausal | 54 | 52 | 55 | ||||||
| Treatment received/recommended | |||||||||
| Surgery, % segmental mastectomy | 43 | 43 | 43 | ||||||
| Radiation therapy, % yes | 54 | 51 | 56 | ||||||
| Hormonal therapy, % yes | 75 | 80 | 71 | ||||||
| Chemotherapy, % yes | 84 | 85 | 83 | ||||||
| Doxorubicin | 74 | 73 | 75 | ||||||
| Cyclophosphamide | 82 | 86 | 79 | ||||||
| Methotrexate | 12 | 14 | 10 | ||||||
| Fluorouracil | 18 | 19 | 17 | ||||||
| Paclitaxel | 21 | 20 | 21 | ||||||
| Performance status | |||||||||
| Karnofsky performance status* | 85.11 | 7.95 | 86.55 | 6.91 | 83.68 | 8.65 | |||
Abbreviations: SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor.
*
Significant group difference, P < .05.